Home » Newsletters » BioWorld Science

BioWorld Science

March 7, 2001

View Archived Issues

Sheffield reports progress update

StemCells receives SBIR grant for liver disease research

Millennium and ImmunoGen establish oncology collaboration

Positive phase III results announced for Metvix PDTas treatment of actinic keratosis

Immune Response vaccine shows protective and inhibitory properties in preclinical tumor models

Synthesis and biological activity of FR-203903, a new antifungal agent

First demonstration of efficacy of nonpeptide chemokine receptor antagonist in autoimmune disease

Broad-spectrum, selective chemokine inhibitor with antiinflammatory properties designed at NeoRx

Patient enrollment begins in phase II trial with ThGRF for COPD

Naturally occurring antiinfluenza agent characterized at Fujisawa

MediGene's novel anticancer therapeutic shows promise in phase I

Biogen's disease-modifying psoriasis therapy maintains efficacy upon retreatment

Switch Biotech and TUM enter research alliance on atopic dermatitis

AltaRex's OvaRex shows efficacy and safety in phase II trial

FDA approves multidose formulation of Serono's Gonal-F for ovarian stimulation

Favorable data presented this week for subcutaneous anti-CD11a antibody product for psoriasis

Innogenetics forms new company focused on wound healing

Repligen reports positive phase I results of uridine in mitochondrial disease; phase II planned

Fuji researchers describe new agents for hyperlipidemia and atherosclerosis

Calcium channel antagonists and their use reported in patent by Ortho-McNeil

Staurosporin-derived antitumor agents developed at Kyowa Hakko

Bayer claims series of metabotropic glutamate receptor antagonists

Synthesis and use of new Lilly compounds active as modulators of neuronal Ca2+ channels

MMP inhibitors in development at Pharmacia for cancer and other disorders

New inhibitors of MTP and their use in lipid disorders, diabetes, obesity, etc.

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...